表紙
市場調査レポート

主要先進国における非小細胞肺癌治療薬市場 〜2021年:免疫治療の台頭による市場成長の牽引と第二の競合力

Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line

発行 GBI Research 商品コード 340979
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
主要先進国における非小細胞肺癌治療薬市場 〜2021年:免疫治療の台頭による市場成長の牽引と第二の競合力 Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
出版日: 2015年09月01日 ページ情報: 英文 113 Pages
概要

非小細胞肺癌は世界的にみて二番目に多い癌となっています。ジェネリックの化学療法から、様々なサブタイプによる複雑な治療へと変化しています。非小細胞肺癌市場は2014年の61億米ドルからCAGR8.5%で拡大し、2021年には109億米ドルになると予測されています。

当レポートでは、非小細胞肺癌の概要と治療薬市場動向、上市済みおよびパイプラインの動向、市場発展予測などをまとめています。

第1章 目次

第2章 イントロダクション

  • 疾患のイントロダクション
  • 疫学
  • 病因と病態生理学
  • 症状
  • 診断
  • 予後
  • 治療
  • 上市済み製品ヒートマップ

第3章 上市済み製品

  • 概要
  • Chemotherapies
  • Alimta - Eli Lilly
  • Abraxane - Celgene Corporation
  • Tarceva - Roche
  • Iressa - AstraZeneca
  • Gilotrif - Boehringer Ingelheim
  • Xalkori - Pfizer
  • Avastin - Roche
  • Cyramza - Eli Lilly
  • Opdivo - Bristol-Myers Squibb
  • Zykadia - Novartis
  • Alectinib - Roche
  • 結論

第4章 非小細胞肺癌パイプライン

  • 概要
  • 作用機序と標的
  • 治験
    • 失敗率
    • 治験規模
    • 治験サマリー
  • 後期パイプライン製品プロファイル
  • パイプラインヒートマップと製品競合性
  • パイプラインの結論

第5章 市場予測

  • 地域別市場
    • 世界市場
    • 北米
    • 欧州5か国
    • 日本
  • 促進因子と障壁

第6章 戦略的統合

  • ライセンシング
  • 共同開発

第7章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC369MR

Executive Summary

Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment landscape based on different NSCLC subtypes and the presence of various molecular aberrations. In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapy. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations.

Scope

The NSCLC market will be valued at $10.9 billion in 2021, growing from $6.1 billion in 2014 at a CAGR of 8.5% -

  • How will immunotherapies such as Keytruda affect growth?
  • What effect will patent expirations of Tarceva and Alimta have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and specific targeted therapies in contrast to the market -

  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
  • What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period -

  • How have promising late-stage therapies performed in clinical trials?
  • How would the approval of Rociletinib affect the competitive landscape?
  • What is the individual commercial forecast for each therapy?

The market forecasts indicate that the US contributes the most to global market value due to a large treatment population and the high price of premium therapies.

  • How will ACoT and market size vary between the eight major markets?
  • How could a change in risk factors such as population age or smoking habits influence the market?
  • Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict NSCLC market growth in eight major markets with epidemiological and ACoT forecasts across the US, Canada, UK, France, Germany, Italy, Spain and Japan, as well as individual drug contributions to market growth.
  • Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Etiology and Pathophysiology
    • 2.3.1. Adenocarcinoma
    • 2.3.2. Squamous Cell Carcinoma
    • 2.3.3. Large Cell Carcinoma
    • 2.3.4. Immunotherapy
  • 2.4. Symptoms
  • 2.5. Diagnosis
  • 2.6. Prognosis
  • 2.7. Treatment
    • 2.7.1. Treatment Algorithm
    • 2.7.2. First-Line Treatment
    • 2.7.3. Maintenance Therapy
    • 2.7.4. Second-Line Treatment
    • 2.7.5. Third-Line Therapy
    • 2.7.6. Adjuvant Therapy
  • 2.8. Marketed Product Heatmaps

3. Marketed Products

  • 3.1. Overview
  • 3.2. Chemotherapies
  • 3.3. Alimta - Eli Lilly
  • 3.4. Abraxane - Celgene Corporation
  • 3.5. Tarceva - Roche
  • 3.6. Iressa - AstraZeneca
  • 3.7. Gilotrif - Boehringer Ingelheim
  • 3.8. Xalkori - Pfizer
  • 3.9. Avastin - Roche
  • 3.10. Cyramza - Eli Lilly
  • 3.11. Opdivo - Bristol-Myers Squibb
  • 3.12. Zykadia - Novartis
  • 3.13. Alectinib - Roche
  • 3.14. Conclusion

4. NSCLC Pipeline

  • 4.1. Overview
  • 4.2. Mechanisms of Action and Targets in the Pipeline
  • 4.3. Clinical Trials
    • 4.3.1. Failure rate
    • 4.3.2. Clinical Trial Duration
    • 4.3.3. Clinical Trial Size
    • 4.3.4. Clinical Trial Summary
  • 4.4. Late-Stage Pipeline Product Profiles
    • 4.4.1. Ganetespib - Synta Pharmaceuticals
    • 4.4.2. Yervoy - Bristol-Myers Squibb
    • 4.4.3. Custirsen - Oncogenex Pharmaceuticals
    • 4.4.4. Atezolizumab - Roche
    • 4.4.5. Necitumumab - Eli Lilly
    • 4.4.6. Patritumab - Daiichi Sankyo
    • 4.4.7. Selumetinib - AstraZeneca
    • 4.4.8. Rociletinib - Clovis Oncology
    • 4.4.9. AZD-9291 - AstraZeneca
    • 4.4.10. Vaxira - Recombio
    • 4.4.11. Keytruda - Merck
    • 4.4.12. TG4010 - Transgene
    • 4.4.13. Veliparib - AbbVie
    • 4.4.14. Abemaciclib - Eli Lilly
    • 4.4.15. Bavituximab - Peregrine Pharmaceuticals
  • 4.5. Pipeline Heatmaps and Product Competitiveness
    • 4.5.1. Product Competitiveness Framework
  • 4.6. Pipeline Conclusion

5. Market Forecast

  • 5.1. Geographical Markets
    • 5.1.1. Global Markets
    • 5.1.2. North America
    • 5.1.3. Top Five EU Countries
    • 5.1.4. Japan
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Strategic Consolidations

  • 6.1. Major Licensing Deals
    • 6.1.1. Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202
    • 6.1.2. Novartis Enters into Licensing Agreement with Antisoma
    • 6.1.3. Ariad Pharma Enters into a Collaboration Agreement with Merck
    • 6.1.4. Astellas Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib
  • 6.2. Major Co-Development Deals
    • 6.2.1. Pfizer Enters into Co-Development Agreement with Merck
    • 6.2.2. Merck Enters into Co-Development Agreement with Endocyte
    • 6.2.3. GlobeImmune Enters into Agreement with Celgene
    • 6.2.4. Amgen Enters into Co-Development Agreement with Takeda Pharmaceutical

7. Appendix

  • 7.1. References
  • 7.2. Abbreviations
  • 7.3. Research Methodology
    • 7.3.1. Secondary Research
    • 7.3.2. Marketed Product Profiles
    • 7.3.3. Late-Stage Pipeline Candidates
    • 7.3.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 7.3.5. Product Competitiveness Framework
    • 7.3.6. Pipeline Analysis
    • 7.3.7. Forecasting Model
    • 7.3.8. Deals Data Analysis
  • 7.4. Expert Panel Validation
  • 7.5. Contact Us
  • 7.6. Disclaimer

List of Tables

  • Table 1: NSCLC, Tumor Node Metastasis Classification, 2015
  • Table 2: NSCLC, Eastern Co-operative Oncology Group Criteria, 2015
  • Table 3: NSCLC, Treatment Options, 2015

List of Figures

  • Figure 1: NSCLC, Global, Molecular Characteristic Frequency (%)
  • Figure 2: NSCLC, Market Heatmap, First-Line Products
  • Figure 3: NSCLC, Market Heatmap, Maintenance Products
  • Figure 4: NSCLC, Market Heatmap, Second-Line Products
  • Figure 5: NSCLC, Pipeline Overview
  • Figure 6: NSCLC, Pipeline Molecular Targets
  • Figure 7: NSCLC, Pipeline by Molecular Target and Stage of Development
  • Figure 8: NSCLC, Clinical Trial Attrition Rates
  • Figure 9: NSCLC, Clinical Trial Attrition Rates by Molecule Type
  • Figure 10: NSCLC, Clinical Trial Attrition Rates by Molecular Target
  • Figure 11: NSCLC, Clinical Trial Duration by Molecule Type
  • Figure 12: NSCLC, Clinical Trial Duration by Molecular Target
  • Figure 13: NSCLC, Clinical Trial Size Per Product by Molecule Type
  • Figure 14: NSCLC, Clinical Trial Size Per Product Molecular Target
  • Figure 15: NSCLC, Clinical Trial Size Per Individual Trial by Molecule Type
  • Figure 16: NSCLC, Clinical Trial Size Per Individual Trial by Molecular Target
  • Figure 17: NSCLC, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 18: NSCLC, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 19: NSCLC, Ganetespib Revenue Forecast ($m), 2017-2021
  • Figure 20: NSCLC, Yervoy Revenue Forecast ($m), 2017-2021
  • Figure 21: NSCLC, Custirsen Revenue Forecast ($m), 2018-2021
  • Figure 22: NSCLC, Atezolizumab Revenue Forecast ($m), 2017-2021
  • Figure 23: NSCLC, Necitumumab Revenue Forecast ($m), 2016-2021
  • Figure 24: NSCLC, Patritumab Revenue Forecast ($m), 2020-2021
  • Figure 25: NSCLC, Selumetinib Revenue Forecast ($m), 2019-2021
  • Figure 26: NSCLC, Rociletinib Revenue Forecast ($m), 2017-2021
  • Figure 27: NSCLC, AZD-9291 Revenue Forecast ($m), 2016-2021
  • Figure 28: NSCLC, Vaxira Revenue Forecast ($m), 2018-2021
  • Figure 29: NSCLC, Keytruda Revenue Forecast ($m), 2016-2021
  • Figure 30: NSCLC, TG4010 Revenue Forecast ($m), 2020-2021
  • Figure 31: NSCLC, Veliparib Revenue Forecast ($m), 2019-2021
  • Figure 32: NSCLC, Abemaciclib Revenue Forecast ($m), 2018-2021
  • Figure 33: NSCLC, Bavituximab Revenue Forecast ($m), 2019-2021
  • Figure 34: NSCLC, Pipeline Heatmap, First-Line Products
  • Figure 35: NSCLC, Pipeline Heatmap, Second-Line Products
  • Figure 36: NSCLC, Marketed and Pipeline Product Competitiveness Framework
  • Figure 37: NSCLC, Global Treatment Patterns, 2014-2021
  • Figure 38: NSCLC, Global Market Size ($bn), 2014-2021
  • Figure 39: NSCLC, North America Treatment Usage Patterns, 2014-2021
  • Figure 40: NSCLC, North America, Annual Cost of Therapy, 2014-2021
  • Figure 41: NSCLC, North America, Market Size, 2014-2021
  • Figure 42: NSCLC, Top Five EU Countries, Treatment Usage Patterns, 2014-2021
  • Figure 43: NSCLC, Top Five EU Countries, Annual Cost of Therapy, 2014-2021
  • Figure 44: NSCLC, Top Five EU Countries, Market Size, 2014-2021
  • Figure 45: NSCLC, Japan, Treatment Usage Patterns, 2014-2021
  • Figure 46: NSCLC, Japan, Annual Cost of Therapy, 2014-2021
  • Figure 47: NSCLC, Japan, Market Size, 2014-2021
  • Figure 48: NSCLC, Licensing Deals by Territory, 2006-2015
  • Figure 49: NSCLC, Licensing Deals Overview, 2006-2015
  • Figure 50: NSCLC, Licensing Deals by Molecule Type, 2006-2015
  • Figure 51: NSCLC, Licensing Deals by Molecular Target, 2006-2015
  • Figure 52: NSCLC, Co-Development Deals by Territory, 2006-2015
  • Figure 53: NSCLC, Co-Development Deals Overview, 2006-2015
  • Figure 54: NSCLC Co-Development by Molecule Type, 2006-2015
  • Figure 55: NSCLC, Co-Development by Molecular Target, 2006-2015
Back to Top